CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results ...Middle East

PR Newswire - News
CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results
– Growing physician awareness and usage of VONJO® (pacritinib) drove quarterly double-digit revenue growth – – VONJO® net product revenue exceeded year-end goal with a total of $54 million for 2022 and $21.1 million in the fourth quarter, a 16% increase compared to the third quarter – –...

Hence then, the article about cti biopharma reports fourth quarter and full year 2022 financial results was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( CTI BioPharma Reports Fourth Quarter and Full Year 2022 Financial Results )

Apple Storegoogle play

Last updated :

Also on site :



Latest News